Clinical Professor Adnan Khattak is a medical oncologist with special interests in gastrointestinal / hepatobiliary cancers, melanoma and lung cancer. In addition to his private practice, he works as a Consultant Medical Oncologist at Fiona Stanley Hospital (FSH) where he is also the Medical Oncology Clinical Trials Lead.

Dr Khattak did his initial specialist training at The Queen Elizabeth Hospital and Flinders Medical Centre in Adelaide before going to the UK. He worked as a Clinical Research Fellow in the melanoma unit at the Royal Marsden Hospital in London. He received his Fellowship in Medical Oncology in 2013 and started working as a Consultant at Royal Perth Hospital before transitioning to FSH in 2015.

Dr Khattak is an active researcher, with interests in colorectal cancer, melanoma and cancer immunotherapy. He is the Medical Oncology Clinical Trials Lead at Fiona Stanley Hospital and the Primary Investigator of many Phase 1, 2 & 3 International Clinical Trials. He is the pioneer of early drug development (Phase 1) work at Fiona Stanley Hospital and now leads the largest trials unit in Perth South Metro. He has more than 40 publications at this stage in various peer-reviewed journals including the New England Journal of Medicine, the Lancet Oncology, Journal of Clinical Oncology and European Journal of Cancer. He has also co-authored the National Health & Medical Research Council (NHMRC) guidelines for the management of advanced colorectal cancer (2017).

He has presented his research at a number of National and International scientific meetings and has been invited as an international visiting speaker to Hong Kong, Taiwan, Saudi Arabia, China, Singapore and India. His current research projects include blood-based biomarkers (circulating tumour cells and circulating tumour DNA) of response and resistance to immunotherapy in cancer (lung, GI & melanoma).

Dr Khattak is also leading an early stage bowel cancer translational research project (Notch pathway) aimed at identifying patients at high risk of disease relapse and those that are less likely to benefit from post-operative chemotherapy.

He is the recipient of a number of prestigious research awards including Cancer Council WA Suzanne Cavanagh Young Investigator Award, Spinnaker Health Research Foundation Collaborative research grant, MSD Young Investigator award, NHMRC Developmental grant and Royal Perth Hospital Medical Research Foundation Award. He is the Chief Investigator/Associate Investigator of research grants in excess of $2 million.